Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Accelerate translational research through innovation across CTSA Program Consortium—funding for new approaches, technologies, resources, and models.
Funder: National Institutes of Health
Due Dates: June 16, 2025 | October 17, 2025 | February 18, 2026 | June 15, 2026 | October 19, 2026 | February 17, 2027 | June 15, 2027 | October 19, 2027 (New/Renewal/Resubmission)
Funding Amounts: Up to $650,000 direct costs per year for each phase (UG3 and UH3); maximum project period is 5 years (UG3: 1–3 years, UH3: 2–4 years).
Summary: Supports collaborative, innovative projects to accelerate translational research by developing, demonstrating, and disseminating new approaches, technologies, or models across the CTSA Program Consortium and beyond.
Key Information: Limited competition; requires collaboration among at least three eligible organizations; strict eligibility and submission requirements.
Description
This opportunity supports collaborative, multi-institutional projects that accelerate the pace and impact of translational research. The program funds the development, demonstration, and broad dissemination of innovative solutions—such as new approaches, technologies, resources, or models—that can transform translational science and bring more treatments to patients more quickly. Projects must leverage the strengths of the Clinical and Translational Science Award (CTSA) Program Consortium and are expected to have a broad, disease-agnostic impact.
The award uses a two-phase cooperative agreement mechanism (UG3/UH3), with the UG3 phase focused on development and feasibility assessment, and the UH3 phase supporting dissemination, implementation, and evaluation of the solution across multiple CTSA hubs and stakeholders.
